Deal Details
Convertible Notes Offering
Summary
Baird served as co-manager on this offering
About
Exact Sciences Corporation (“Exact” or the “Company”) (NASDAQ: EXAS) recently completed an upsized convertible note offering of $1.150 billion 0.375% Convertible Senior Notes due 2028, which includes the underwriters’ 30-day option to purchase up to an additional $150 million aggregate principal amount of the Notes solely to cover over-allotments. Exact intends to use the net proceeds received from this offering for general corporate purposes, which may include the repayment or repurchase of debt, working capital and possible acquisitions.Exact is a leading provider of cancer screening and diagnostic tests. The Company relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. The Company unites visionary collaborators to help advance the fight against cancer. Exact is headquartered in Madison, Wisconsin.
CONTACT US TO LEARN MORE
- Date
- February 2020
- Company
- Exact Sciences Corporation
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
